Thomas Edelmann

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

Wolfram Pönisch, Barbara Moll, Simone Heyn et al. · Journal of Cancer Research and Clinical Oncology · 2012 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Wolfram Pönisch, Barbara Moll, Marc Andrea et al. · Journal of Cancer Research and Clinical Oncology · 2013 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial <scp>OSHO</scp> – #077

Wolfram Pönisch, Simone Heyn, Juliane Beck et al. · British Journal of Haematology · 2013 · 32 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

Wolfram Pönisch, Bruno Holzvogt, Madlen Plötze et al. · Journal of Cancer Research and Clinical Oncology · 2014 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Early inhibition of endothelial retinoid uptake upon myocardial infarction restores cardiac function and prevents cell, tissue, and animal death

Katarina Danzl, Christian Doppler, Clemens Nebert et al. · Journal of Molecular and Cellular Cardiology · 2018 · 21 citations · Full text

Medicine, Cardiology, Pharmacology +15